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INTRODUCTION 
Hemodialysis (HD) is the most frequently used form 
of renal replacement therapy for many patients with 
end-stage renal disease (ESRD). One of the leading cau-
ses of morbidity and mortality in HD patients is cardio-
vascular disease (CVD). In 1998, the National Kidney 
Foundation reported that, at er stratifying for age, race, 
and gender, mortality from CVD in HD patients was 
10-30 times greater than in the general population (1).
Despite the neutral ef ect, HD is associated with a 
number of biochemical abnormalities including dysli-
pidemia and oxidative stress. Renal dyslipidemia is 
caused by certain dialysis-related parameters, which 
may signii cantly af ect lipoprotein metabolism and 
modify the composition of plasma lipoproteins. It 
appears that a reduced catabolism and clearance of 
Apo B-containing lipoproteins of hepatic and intesti-
nal origin constitutes the main abnormality.
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Dyslipidemia in HD patients is distinct from that in 
the general population. Common lipid abnormality in 
HD patients is hypertriglyceridemia because patients 
with chronic renal failure mainly manifest insulin resi-
stance activating hormone sensitive lipase; consequen-
tly, it leads to raised free fatty acids and the production 
of very low-density lipoprotein (VLDL) (2).
Other lipid abnormalities seen in HD patients are 
reduced concentrations of high-density lipoprotein 
(HDL) cholesterol level and increased levels of intact 
or partially metabolized triglyceride-rich Apo B-con-
taining lipoproteins in VLDL, intermediate-density 
lipoprotein (IDL), and small low-density lipoprotein 
(LDL) particles (3).
Among the reasons of lipid abnormalities are mal-
nutrition and hypoalbuminemia present in many of 
these patients. Hypoalbuminemia is associated with 
pathophysiological changes in lipid metabolism by 
decreasing oncotic pressure, which stimulates hepa-
tic synthesis of albumin and other proteins, including 
apolipoproteins, thus also leading to increase in total 
cholesterol, triglycerides and LDL, and decrease in 
HDL (4).
Excessive oxidative stress has long been demonstrated 
in hemodialysis patients due to reduced antioxidant 
capacity and increased pro-oxidant activity with nega-
tive ef ects on carbohydrates, lipids and body proteins.
During HD treatment, uremic toxicity, malnutrition 
and progressive decline in kidney function can lead to 
hyperproduction of agents from oxidative metabolism 
with pro-oxidant function, including reactive oxygen 
species (ROS) and uremic toxins. Losses of antioxi-
dants via dialysis, the use of low biocompatible mem-
branes and purity of dialysis water are the factors that 
may be responsible for reduced antioxidant defense 
mechanisms in HD patients.
Superoxide dismutase (SOD) is the i rst-line defense 
against the deleterious ef ects of ROS (5). It specii cally 








Dyslipidemia accompanied by excessive oxidative 
stress in HD patients accelerates the process of athe-
rosclerosis, resulting in cardiovascular complications. 
h e present study evaluated the relationship between 
dyslipidemia and oxidative stress by evaluating lipid 




h e study was designed as a cross-sectional, clinical, 
comparative study, which was conducted at the Depar-
tment of Hemodialysis, Sarajevo University Clinical 
Centre (SUCC). Based on the duration of hemodialysis 
therapy, study groups were divided into two subgroups 
of patients on HD for more than three months but less 
than i ve years (HD <5 years; n=48) and patients on 
HD for i ve years or more than i ve years (HD ≥5 years; 
n=52). Control group (n=50) consisted of age- and gen-
der-matched, apparently healthy individuals without su-
bjective and objective indicators of chronic renal disease.
Patients were on chronic HD program for a period lon-
ger than three months, for four hours three times a week 
(bicarbonate dialysis), with low-l ux dialysate and Frese-
nius Medical Care dialysis monitors, 4008S with UF. h e 
majority of patients (63%) were dialyzed through hemo-
diai ltration, while 37% patients were dialyzed through 
hemodialysis. h e most common type of access for per-
forming dialysis in HD patients was arteriovenous i stu-
la (AVF, 79%), then tunnelled central venous catheter 
(12%) and temporary central venous catheter (9%).
Patients were regarded non-eligible for the study if any 
of the following criteria was met: age younger than 18 
or more than 70 years, presence of malignancy, febrile 
disorders, acute or chronic inl ammatory disease or 
coronary heart diseases during the study period. 
Subjects of the control group had no history of inl am-
matory, autoimmune or rheumatic diseases, hyperlipi-
demia, hypertension or coronary heart diseases. None 
of the control subjects had received any medication, 
was current smoker or alcohol consumer. 
Upon careful explanation of the study procedure, an 
informed consent in writing was obtained from all pa-
tients and healthy controls.  h e study was approved 
by the SUCC Ethics Committee. Investigations were 
carried out in accordance with the Declaration of Hel-
sinki as revised in 2000.
Methods
Blood collection was performed under aseptic pre-
cautions at the SUCC Department of Hemodialysis 
immediately before each HD session, according to 
days of the week and in the morning, at ernoon and 
evening shit s. Blood was collected from antecubital 
vein using 10-mL vacutainer tubes (BD Vacutainer 
Systems, Plymouth, UK). Each specimen was centri-
fuged at 2000 g for 10 min to separate serum, which 
was stored at -80 °C until SOD analysis. 
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Serum SOD concentration was determined by the 
commercially available quantitative sandwich enzy-
me-linked immunosorbent assay (ELISA) (CSB-EL-
022399HU, Cusabio Company, China) according to the 
manufacturer’s instructions at the Department of Bio-
chemistry, Faculty of Medicine, University of Sarajevo. 
h ese assays employ the quantitative sandwich enzyme 
immunoassay technique. Antibody specii c for each 
enzyme is pre-coated onto a microplate. Standards and 
samples are pipetted into the wells and any enzyme 
present is bound by the immobilized antibody. At er 
adding biotin-conjugated antibody specii c for each 
enzyme and avidin-conjugated horseradish peroxidase, 
the substrate solution is added to the wells and colors 
develop in proportion to the amount of enzymes bound 
in the initial step. In the i nal step, color intensities were 
measured in appropriate wavelengths, on the STAT 
FAX-2100 microplate reader (Awareness Technology 
Inc., USA). h e enzyme levels were reported as U/mL.
Lipid parameters were determined on an automated 
apparatus (Dimension RxL Max, Dade Behring, Ger-
many) at the Institute of Clinical Chemistry and Bio-
chemistry, SUCC, using standard methods. Serum total 
cholesterol (TC) was measured by the cholesterol oxida-
se method, while HDL cholesterol levels were determi-
ned by direct homogeneous enzymatic method. Serum 
triglyceride (TG) levels were assayed at er enzymatic 
hydrolysis by simultaneous enzymatic determination of 
glycerol. LDL cholesterol was calculated using the for-
mula of Friedewald et al. (6). h e reference values of TG, 
TC, LDL cholesterol, HDL cholesterol (according to the 
reagent manufacturer’s instructions) are as follows: TG 
0.11-1.7 mmol/L, TC 3.1-5.2 mmol/L, HDL cholesterol 
1.06-1.94 mmol/L, and LDL cholesterol 2-4.3 mmol/L.
Kolmogorov-Smirnov test of normality was used to 
test the normality and variance homogeneity of data. 
Data were expressed as mean ± SEM for normally 
distributed variables and as median and interquartile 
ranges for skewed variables. Categorical variables were 
shown as frequencies. Dif erence in normally distri-
buted data was tested by independent t-test. Dif eren-
ce in the values of parameters that showed skewed dis-
tribution was assessed by Kruskal-Wallis test, followed 
by Mann-Whitney U test. Correlations between the 
variables were assessed by Pearson’s test. To determi-
ne the accuracy and respective best cut-of  values of 
serum SOD level and lipid proi le for dif erentiating 
hemodialysis patients from healthy controls, the Rece-
iver Operating Characteristic (ROC) curves and the-
ir corresponding areas under the curve (AUC) were 
used. Accuracy rate of diagnosing measures was cal-
culated by use of 95% coni dence interval (95% CI). 
h e values of p<0.05 were considered statistically si-
gnii cant in all comparisons. Data were analyzed using 
the Statistical Package for the Social Sciences (SPSS) 
sot ware version 13 (IBM, Chicago, Illinois, USA), and 
the results are presented in tables or i gures.
RESULTS
As shown in Table 1, HD patients were signii cantly 
older than healthy subjects (p<0.05). h e percentage 
of males was higher than that of females in both HD 
groups, yielding a signii cant dif erence as compared 
with the control group (p<0.05).
Table 1.
Age and gender of HD patients with dif erent duration of 
dialysis therapy and the control group.
Variables
HD group
< 5 years (n=48)
HD group
≥ 5 years (n=52)
Control group
(n=50)
Age (years) 53.4 ± 1.68*≈ 54.8 ± 1.67* 41.72 ± 1.39
Gender
male 30 (62.5%)*≈ 30 (57.7%)* 18 (36%)
female 18 (40%)*≈ 22 (42.3%)* 32 (64%)
Data are presented as mean ± SEM; n (%); HD-hemodialysis; NS-not signifi cant; 
p-probability * p<0.05 - compared with control group ≈ NS - compared with HD 
group ≥ 5 years
Fig. 1 shows the median and interquartile range of se-
rum SOD concentration in control and HD groups. Me-
dian serum SOD concentration in HD <5 year group 
was statistically signii cantly higher compared with the 
control group [12.29 (10.85-14.15) vs.11.04 (9.42-12.99) 
U/mL; p<0.05]. h ere was no signii cant dif erence in 
serum SOD concentration between HD patients who 
were on hemodialysis therapy for i ve and more than 
i ve years [12.97 (10.27-14.56) U/mL] and healthy con-
trol subjects. h ere was no signii cant dif erence in se-
rum SOD concentration between the two HD groups.
Fig. 1. Box-and-whisker plots of serum SOD concentration 
(U/ml) in HD patients with dif erent duration of dialysis 
therapy and healthy controls.
Data are presented as median (25th and 75th percentiles); 
SOD - superoxide dismutase; HD - hemodialysis * compared 
with control group ** compared with HD group ≥ 5 years
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As shown in Table 2, serum concentrations of TC, 
LDL cholesterol and HDL cholesterol were signii can-
tly lower in both groups of HD patients in comparison 
with control subjects (p<0.0005). h e values of these 
lipid parameters were higher in patients of HD <5 year 
group than in patients of HD ≥5 year group, but the 
dif erences were not signii cant. h ere were no signii -
cant dif erences in serum TG concentrations between 
the study groups.
Table 2. 
Comparison of serum concentrations of total cholesterol, triglycerides, low-density lipoprotein and high-density lipoprotein 
between hemodialysis patients with dif erent duration of hemodialysis therapy and healthy controls.
Parameters
HD group < 5 years
(n=48)




HD group < 5 years
vs HD group ≥ 5 years
p=
HD group < 5 years
vs Control group
p=
HD group ≥ 5 years
vs Control group
p=
TC (mmol/L) 4.4 ± 0.13 4.2 ± 0.11 5.7 ± 0.16 NS 0.0005 0.0005
TG (mmol/L) 1.85 (1.27-2.38) 1.59 (1.27-2.25) 1.46 (0.96-2.3) NS NS NS
LDL (mmol/L) 2.6 (2.10-2.86) 2.37 (1.91 -2.62) 3.35 (2.86-3.81) NS 0.0005 0.0005
HDL (mmol/L) 0.89 (0.76-1.08) 0.85 (0.73-1.12) 1.28 (1.15-1.63) NS 0.0005 0.0005
Data are presented as mean ± SEM; median (25th and 75th percentiles); TC-total cholesterol; TG - triglycerides; LDL-Low-density lipoprotein;
HDL - High-density lipoprotein; NS - not signifi cant; p - probability
h e ROC curve for serum SOD level in total study 
sample of HD patients vs. healthy control subjects 
with signii cant AUC is shown in Figure 2A. h e op-
timal cut-of  value for serum SOD level in dif eren-
tiating HD patients from healthy subjects selected by 
ROC curve was 12.05 U/mL, with sensitivity of 57%, 
specii city of 72%, positive predictive value of 80% and 
negative predictive value of 45% (Table 3). h e overall 
accuracy of serum SOD concentration in discrimina-
ting HD patients was 62%. Serum SOD level had fair 
diagnostic accuracy for dif erentiation between HD 
patients and healthy control (AUC 0.716; p=0.03). 
h e ROC curve of TC, LDL and HDL for dif eren-
tiation between HD patients and healthy controls is 
shown in Figure 2B. As shown in Table 3, the optimal 
cut-of  value for LDL in dif erentiating HD patients 
from healthy subjects, selected by ROC curve (AUC 
0.869; p=0.0005) was 2.705 mmol/L (sensitivity 88%, 
specii city 72%, positive predictive value 63% and ne-
gative predictive value 92%). Moreover, ROC analysis 
also suggested 1.025 mmol/L as optimal cut-of  point 
for HDL in dif erentiating HD patients from healthy 
controls (AUC 0.864; p=0.0005, sensitivity 92%, speci-
i city 74%, positive predictive value 61% and negative 
predictive value 94%). 
h e optimal cut-of  value for TC selected by ROC cur-
ve (AUC 0.855; p=0.0005) was 4.85 mmol/L, yielding a 
sensitivity of 86%, specii city of 76%, positive predicti-
ve value of 64% and negative predictive value of 91%. 
h e overall accuracy of TC in identifying HD patients 
was highest (79%), followed by LDL (77%) and HDL 
(76%). According to ROC analysis, serum TC, LDL 
and HDL concentrations had good diagnostic accura-
cy in dif erentiating HD patients from healthy subjects.
Fig. 2. (A) Receiver operating characteristic (ROC) curve of 
serum SOD level for dif erentiation between HD patients and 
healthy controls. (B) ROC curve of low-density lipoprotein 
(LDL), High-density lipoprotein (HDL) and total cholesterol 
(TC) for dif erentiation between HD patients and healthy 
controls.
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Table 3. 
Optimal cut-of , area under the curve with 95% coni dence interval (AUC, 95% CI), sensitivity, specii city, positive and negative 
predictive value, overall accuracy of serum SOD level, low-density lipoprotein, high-density lipoprotein and total cholesterol in 





AUC (95%CI) SEN SPE PPV NPV Overall accurate
Hemodialysis patients vs healthy controls
SOD (≥ 12.05 U/mL) 0.606 (0.51 -0.70) 57% 72% 80% 45% 62% 0.03
LDL (≤ 2.705 mmol/L) 0.855 (0.79-0.92) 88% 74% 63% 92% 77% 0.0005
HDL (≤ 1.025 mmol/L) 0.864 (0.80-0.92) 92% 70% 61% 94% 76% 0.0005
TC (≤ 4.85 mmol/L) 0.869 (0.80-0.93) 86% 76% 64% 91% 79% 0.0005
AUC-Area under the curve; CI-Confi dence Interval; SOD-superoxide dismutase; LDL-Low-density lipoprotein; HDL-High-density lipoprotein; TC-total 
cholesterol; SEN-sensitivity; SPE- specifi city;PPV-positive predictive value; NPV-negative predictive value; p-probability
DISCUSSION
h e clearly coni rmed fact that patients on chronic 
HD are at an increased risk of cardiovascular morbidi-
ty and mortality has stimulated a whole range of rese-
arch aiming at identifying appropriate biomarkers to 
optimize the diagnosis and treatment of this group of 
patients. In this regard, the role of oxidative stress and 
dyslipidemia as potentially important processes is pri-
marily attributed to atherosclerotic changes in blood 
vessels of HD patients.
Oxidative stress, as a result of the imbalance between 
toxic compounds and defense mechanisms, is associa-
ted with numerous adverse complications in patients 
with chronic renal disease. Consequently, excessive 
production of ROS or toxic compounds is accompa-
nied by the lack of antioxidants, which is particularly 
pronounced in hemodialysis patients.
Superoxide dismutase is a metalloenzyme present in 
all eukaryotic cells, included in the front line defense 
against ROS mediated injury. Recent studies of SOD 
activity in HD patients found conl icting results (7,8). 
Results of our study showed signii cantly increased va-
lues of serum SOD concentration in HD <5 year gro-
up of patients compared to control subjects. h ere was 
no signii cant dif erence in serum SOD concentration 
between HD patients who were on HD for i ve and 
more than i ve years and healthy control subjects. Our 
i ndings are in accordance with the study conducted 
by Hacisevki (9), which included 64 patients on HD 
and a control group of 22 healthy subjects. SOD con-
centration was increased in dialysis patients as compa-
red with healthy subjects. Kose et al. (10) report an in-
creased erythrocyte SOD activity in the post-dialysis 
group when compared with the pre-dialysis group. 
Contrary to our observation, Mooujerlo (11) showed a 
decreased activity of the SOD enzyme in HD patients, 
whereas Weinstein et al. (12) report no change in the 
SOD enzyme levels due to HD. 
We presume that the increased activity of SOD in HD 
patients may be a defense mechanism of the cell due to 
the increased production of free radicals in renal fai-
lure. Decreased activity of antioxidants in maintenan-
ce HD patients may contribute to the increased oxida-
tive damage and development of renal complications. 
Loss of antioxidants through dialysis membrane and 
the use of incompatible one are factors that may be 
responsible for the imbalance between oxidants and 
antioxidant mechanisms in patients on HD.
Progressive renal failure is associated with lipoprotein 
abnormalities and dyslipidemia. However, dyslipide-
mia may not appear as hyperlipidemia in the majority 
of HD patients. h is gives rise to various dif erences, 
even though the pathogenesis and lipid proi le phe-
notype in HD patients are similar to the pre-dialysis 
period. 
Some of our i ndings are concordant with previous 
similar reports but vary from the others. Contrary to 
other results, we observed a statistically signii cantly 
lower TC level and no signii cant dif erences in serum 
TG concentrations in HD patients with dif erent du-
ration of HD therapy compared to control subjects. 
h e possible explanation of our results is the impact of 
cytokinemia, which may be related to impaired remo-
val of lipid substances (13). 
In both HD patient groups, LDL and HDL choleste-
rol were signii cantly lower in comparison to controls. 
h is hypo-HDL cholesterol level in ESRD patients 
on dialysis is agreed upon by several authors (14,15) 
and could be due to a decrease in the activity of le-
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cithin-cholesterol acyltransferase (LCAT) responsible 
for the decrease in the esterii cation of free cholesterol 
in HDL cholesterol, decreased HDL components, and 
an increase in the activity of cholesterol ester transfer 
protein (CETP), implying an increase in HDL esteri-
i ed cholesterol transfer to LDL (16).
Removal of excess lipids from the vascular wall by 
HDL cholesterol is a key anti-atherogenic mechanism 
of HDL-cholesterol. It has been shown that HDL cho-
lesterol inhibits the expression of E-selectin or other 
adhesion molecules by vascular endothelial cells expo-
sed to cytokines. h is results in decreased binding of 
inl ammatory cells, which is consistent with functi-
onal inhibition of atherosclerosis. Interruption of a 
signaling pathway involving sphingosine kinase acti-
vation and the synthesis of sphingosine-1-phosphate 
has been proposed as a mechanism for the anti-athe-
rogenic ef ects of HDL cholesterol on the expression of 
adhesion molecules (17).
Our results are consistent with those of several recent 
studies which have reported normal or low levels of 
LDL cholesterol in HD patients (18,19). Although the 
results of a large number of studies show that LDL 
level is not elevated in CKD patients, LDL particles 
are usually smaller, denser and more atherogenic in 
their form. Accumulation of small LDL particles is 
associated with a higher rate of cardiovascular events. 
Previous studies showed an increased level of LDL in 
dialysis-dependent CKD patients compared to he-
althy controls and low LDL as a risk factor for CVD 
development. As a consequence of the signii cantly 
modii ed lipid subfraction turnover, retention time of 
lipoproteins in the circulation is prolonged. h us, li-
poproteins are at risk of post-ribosomal modii cation, 
which includes glycation, oxidation, and carbamylati-
on. h ese modii ed lipoproteins have reduced ai  nity 
for the classic LDL receptors and are taken up by the 
scavenger receptors, especially increased in uremia, 
on the macrophage surface. h e i nal result is the ac-
cumulation of cholesterol and the formation of foam 
cells, resulting in the development of atherosclerotic 
plaques in the vascular walls. h ere are several mech-
anisms by which small dense LDL is likely to play a 
causal role in promoting atherosclerosis: increasing 
superoxide generation (O-2) from the endothelium, 
decreasing basal nitric oxide (NO) production, incre-
asing trans-endothelial i ltration, reducing ai  nity for 
LDL receptors, and increasing binding to intimal pro-
teoglycans (20). 
In addition, results of the previous studies show that 
chronic renal failure patients treated with HD have an 
increased prevalence of IDL and lipoprotein(a) (Lp(a)) 
(21). Hirowatari et al. report lower levels of HDL cho-
lesterol and LDL cholesterol, and higher level of IDL 
cholesterol in ESRD patients on HD (22). As a result 
of many studies, Shoji et al. propose that the IDL cho-
lesterol level is the possible target in the management 
of dyslipidemia in renal disease (23).
Current literature suggests that the levels of Lp(a) in-
crease as kidney disease progresses and decline at er 
kidney transplantation. Some authors showed a de-
crease in the clearance of Lp(a) in HD patients, de-
monstrating the involvement of the kidney in its eli-
mination. Lp(a) predicts the development of carotid 
atheromatous disease and vascular events in dialysis 
patients (24).
It should be noted that dialysis itself does not af ect the 
serum lipid proi le. However, certain parameters clo-
sely related to dialysis may have a signii cant inl uence 
on lipoprotein metabolism and lead to changes in the 
lipidogram of HD patients. Some of them are dialysis 
membrane, dialysis l uid, anticoagulant therapy, and 
treatment with phosphate binders such as sevelamer 
hydrochloride and sevelamer hydrocarbonate. h e use 
of high-velocity polysulfonic or cellulose membranes 
instead of low-membrane membranes is associated 
with a signii cant reduction in TG levels and increa-
sed levels of apolipoprotein A and HDL cholesterol. 
h e use of bicarbonate dialysis can increase the level 
of HDL cholesterol compared to acetic dialysis (25). 
Another possible factor that can potentially af ect li-
poprotein metabolism in HD patients is the repeated 
use of heparin as an anticoagulant. Heparin releases li-
poprotein lipase from the endothelial surface and thus 
its chronic use may result in lipoprotein lipase deple-
tion and defective catabolism of TG-rich lipoproteins 
(3).
According to the ROC analysis, our study revealed 
that, due to the poor diagnostic accuracy, serum SOD 
concentration could not be used as an independent 
marker in dif erentiating HD patients from healthy su-
bjects, or in dif erentiating HD patients with dif erent 
HD duration. In contrast, serum LDL, HDL and TC 
levels had good diagnostic accuracy in dif erentiating 
HD patients from healthy subjects. Since by searching 
the literature we found no similar study, we could not 
compare our results with results of other authors.
CONCLUSION
In our study, oxidative stress was characterized by a 
signii cant increase of serum SOD concentration in 
ESRD patients on HD compared to controls. In respect 
of lipid proi le, it was observed that serum levels of TC, 
LDL and HDL were signii cantly lower in HD patients 
when compared to control subjects. However, serum 
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TG levels did not dif er signii cantly between the study 
groups. h e accompanying serum lipid alteration in 
HD patients increases the risk of atherosclerosis and 
favors a higher incidence of cardiovascular complica-
tions. h erefore, lipid regulation must be instituted to 
decrease the risk of complications in HD patients.
h e common pathogenesis of oxidative stress and 
dyslipidemia in HD patients has not yet been fully 
clarii ed and new studies regarding this pathogenesis 
are therefore needed. h us, at er HD, ESRD patients 
become more vulnerable to cardiac and cerebrovas-
cular accidents due to increased oxidative stress and 
compromised lipid status. New approaches are to be 
adapted with reference to dialysis membrane and dia-
lysis technique.
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Uvod/cilj: Hemodijaliza (HD) je povezana s brojnim biokemijskim abnormalnostima uključujući dislipidemiju i oksidativni 
stres. Cilj istraživanja bio je ispitati aktivnost i utvrditi povezanost enzima superoksid dismutaze (SOD) s parametrima 
lipidnog profi la kod bolesnika na HD. Metode: Presječnom studijom obuhvaćeno je 100 HD bolesnika koji su podijeljeni u 
dvije skupine: bolesnici koji su bili liječeni pomoću HD više od tri mjeseca, ali manje od pet godina (HD <5 godina, n=48) 
i bolesnici koji su bili liječeni pomoću HD pet godina i više (HD ≥5 godina, n=52). Kontrolnu skupinu (n=50) činile su po 
dobi i spolu odgovarajuće zdrave osobe bez subjektivnih i objektivnih pokazatelja bubrežne bolesti. Uzorci krvi služili su 
za određivanje koncentracija SOD, ukupnog kolesterola, triglicerida (TG), lipoproteina male gustoće (LDL) i lipoproteina 
velike gustoće (HDL). Serumska koncentracija SOD određena je metodom ELISA upotrebom komercijalnog kita. Rezultati: 
Serumska koncentracija SOD bila veća kod HD bolesnika u usporedbi sa zdravim kontrolnim osobama. Koncentracija SOD 
u skupini bolesnika na HD <5 godina bila je značajno veća u odnosu na kontrolnu skupinu ispitanika [12,29 (10,85-14,15 
prema 11,04 (9,42-12,99) U/mL (p<0,05)], ali nije utvrđena značajna razlika u koncentraciji SOD između skupina bolesnika 
na HD ≥5 godina [12,97 (10,27-14,56) U/mL] i zdravih ispitanika kontrolne skupine. Uz to, nije bilo značajne razlike u serum-
skoj koncentraciji SOD između HD bolesnika koji su bili liječeni pomoću HD <5 godina i ≥5 godina. Utvrđeno je značajno 
smanjenje koncentracija TC, LDL i HDL u objema skupinama HD bolesnika u odnosu na kontrolnu skupinu (p<0,0005), ali 
razine serumskih TG nisu se značajno razlikovale između promatranih skupina. Rezultati dobiveni ROC analizom pokazali 
su da su serumske razine TC, LDL i HDL u odnosu na serumsku koncentraciju SOD osjetljivije u razlikovanju HD bolesnika 
i zdravih osoba. Zaključak: Na osnovi naših rezultata može se zaključiti da povišena serumska koncentracija SOD, zajedno 
s promjenama lipidnog profi la, povećava rizik od ateroskleroze i kardiovaskularnih komplikacija kod HD bolesnika.
Ključne riječi: hemodijaliza, superoksid dismutaza, dislipidemija
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